收購MSC幹細胞療法技術引發股價暴漲 Neuroscientific Biopharmaceuticals (ASX:NSB) 加速克羅恩病臨試研究

澳洲財經見聞

2025/07/19

神經免疫疾病生物醫學創新公司Neuroscientific Biopharmaceuticals Ltd (ASX股票代碼:NSB) 股價異動，周四飆漲16.67%。

自4月中旬披露收購間充質幹細胞 (MSC) 治療技術StemSmart以來，NSB股價上漲348.72%。

NSB最新價0.175澳元，已發行股本3.33億股，市值5820萬澳元。截止一季度末公司賬面現金結餘449萬澳元。

美國FDA最近批准了首個MSC療法——由市值達20億澳元的澳洲生物科技公司Mesoblast(ASX股票代碼:MSB)提請註冊，該進展重新點燃醫療界對MSC療法臨床研究的熱情並吸引全球投資者目光。

Neuroscientific Biopharmaceuticals 於6月底完成對StemSmart技術的收購。NSB即將上任的董事局主席Robert McKenzie表示，公司正在推動運用StemSmart治療瘻管性克羅恩病的特別准入試驗；若初步結果積極，將可推進至 1/2 期臨試。

（圖片來源：NSB公告）

（圖片來源：NSB公告）

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2552154364"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552154364\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552154364?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-19 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552154364","market":"us","top_or_hot":-1,"title":"收購MSC幹細胞療法技術引發股價暴漲 Neuroscientific Biopharmaceuticals (ASX:NSB) 加速克羅恩病臨試研究","media":"澳洲財經見聞","content":"<html><body><p>神經免疫疾病生物醫學創新公司<strong>Neuroscientific Biopharmaceuticals Ltd (ASX股票代碼:NSB) </strong>股價異動，周四飆漲16.67%。</p>\n<div>\n<div></div>\n</div>\n<p>自4月中旬披露收購間充質幹細胞 (<a href=\"https://laohu8.com/S/NPW.SI\">MSC</a>) 治療技術StemSmart以來，NSB股價上漲348.72%。</p>\n<p>NSB最新價0.175澳元，已發行股本3.33億股，市值5820萬澳元。截止一季度末公司賬面現金結餘449萬澳元。</p>\n<p>美國FDA最近批准了首個MSC療法——由市值達20億澳元的澳洲生物科技公司<a href=\"https://laohu8.com/S/MESO\">Mesoblast</a>(ASX股票代碼:MSB)提請註冊，該進展重新點燃醫療界對MSC療法臨床研究的熱情並吸引全球投資者目光。</p>\n<p>Neuroscientific Biopharmaceuticals 於6月底完成對StemSmart技術的收購。NSB即將上任的<strong>董事局主席Robert McKenzie</strong>表示，公司正在推動運用StemSmart治療瘻管性克羅恩病的特別准入試驗；若初步結果積極，將可推進至 1/2 期臨試。</p>\n<figure><img decoding=\"async\" height=\"494\" src=\"https://static.tigerbbs.com/ec5e90405a53440890016f8c99cbe40b\" width=\"1024\"/></figure>\n<p>（圖片來源：NSB公告）</p>\n<figure><img decoding=\"async\" height=\"249\" src=\"https://static.tigerbbs.com/56dbe5883ff7433198caa0638dc5d49e\" width=\"718\"/></figure>\n<p>（圖片來源：NSB公告）</p>\n</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>收購MSC幹細胞療法技術引發股價暴漲 Neuroscientific Biopharmaceuticals (ASX:NSB) 加速克羅恩病臨試研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n收購MSC幹細胞療法技術引發股價暴漲 Neuroscientific Biopharmaceuticals (ASX:NSB) 加速克羅恩病臨試研究\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1080487607\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/6181633f5a87d6eb7ca4059b1fb9b32c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">澳洲財經見聞 </p>\n<p class=\"h-time smaller\">2025-07-19 10:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>神經免疫疾病生物醫學創新公司<strong>Neuroscientific Biopharmaceuticals Ltd (ASX股票代碼:NSB) </strong>股價異動，周四飆漲16.67%。</p>\n<div>\n<div></div>\n</div>\n<p>自4月中旬披露收購間充質幹細胞 (<a href=\"https://laohu8.com/S/NPW.SI\">MSC</a>) 治療技術StemSmart以來，NSB股價上漲348.72%。</p>\n<p>NSB最新價0.175澳元，已發行股本3.33億股，市值5820萬澳元。截止一季度末公司賬面現金結餘449萬澳元。</p>\n<p>美國FDA最近批准了首個MSC療法——由市值達20億澳元的澳洲生物科技公司<a href=\"https://laohu8.com/S/MESO\">Mesoblast</a>(ASX股票代碼:MSB)提請註冊，該進展重新點燃醫療界對MSC療法臨床研究的熱情並吸引全球投資者目光。</p>\n<p>Neuroscientific Biopharmaceuticals 於6月底完成對StemSmart技術的收購。NSB即將上任的<strong>董事局主席Robert McKenzie</strong>表示，公司正在推動運用StemSmart治療瘻管性克羅恩病的特別准入試驗；若初步結果積極，將可推進至 1/2 期臨試。</p>\n<figure><img decoding=\"async\" height=\"494\" src=\"https://static.tigerbbs.com/ec5e90405a53440890016f8c99cbe40b\" width=\"1024\"/></figure>\n<p>（圖片來源：NSB公告）</p>\n<figure><img decoding=\"async\" height=\"249\" src=\"https://static.tigerbbs.com/56dbe5883ff7433198caa0638dc5d49e\" width=\"718\"/></figure>\n<p>（圖片來源：NSB公告）</p>\n</body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NSB.AU","symbol_name":"NEUROSCIENTIFIC BIOPHARMACEU","start_time":0,"source_url":"https://afndaily.com/%e6%94%b6%e8%b4%admsc%e5%b9%b2%e7%bb%86%e8%83%9e%e7%96%97%e6%b3%95%e6%8a%80%e6%9c%af%e5%bc%95%e5%8f%91%e8%82%a1%e4%bb%b7%e6%9a%b4%e6%b6%a8-neuroscientific-biopharmaceuticals-asxnsb-%e5%8a%a0/","article_id":"2552154364","we_media_id":"1080487607","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552154364","pubTimestamp":1752892572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"澳洲財經見聞","introduction":"提供每日不可缺的商业财经新闻、深度分析以及评论。","home_visible":1,"id":"1080487607","head_image":"https://community-static.tradeup.com/news/6181633f5a87d6eb7ca4059b1fb9b32c"},"summary":"神經免疫疾病生物醫學創新公司Neuroscientific Biopharmaceuticals Ltd (ASX股票代…","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NSB.AU":"NEUROSCIENTIFIC BIOPHARMACEU","MSC":"新濠影汇","BK7067":"生物科技","BK4575":"芯片概念","BK4150":"赌场与赌博"},"translate_title":"Acquisition of MSC Stem Cell Therapy Technology Sparks Stock Price Spike Neuroscientific Biopharmaceuticals (ASX: NSB) Accelerates Crohn's Disease Trial Study","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSC":1,"NSB.AU":1},"content_text":"神經免疫疾病生物醫學創新公司Neuroscientific Biopharmaceuticals Ltd (ASX股票代碼:NSB) 股價異動，周四飆漲16.67%。\n\n\n\n自4月中旬披露收購間充質幹細胞 (MSC) 治療技術StemSmart以來，NSB股價上漲348.72%。\nNSB最新價0.175澳元，已發行股本3.33億股，市值5820萬澳元。截止一季度末公司賬面現金結餘449萬澳元。\n美國FDA最近批准了首個MSC療法——由市值達20億澳元的澳洲生物科技公司Mesoblast(ASX股票代碼:MSB)提請註冊，該進展重新點燃醫療界對MSC療法臨床研究的熱情並吸引全球投資者目光。\nNeuroscientific Biopharmaceuticals 於6月底完成對StemSmart技術的收購。NSB即將上任的董事局主席Robert McKenzie表示，公司正在推動運用StemSmart治療瘻管性克羅恩病的特別准入試驗；若初步結果積極，將可推進至 1/2 期臨試。\n\n（圖片來源：NSB公告）\n\n（圖片來源：NSB公告）","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,productRelease,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}